Silicon Valley craze nears FDA nod

---

1. Key Themes

Theme 1: FDA Reversal on Peptides Opens a Major Consumer Health Market

The FDA is expected to allow compounding pharmacies to produce 14 injectable peptides — a sharp reversal from its prior ban — unlocking a significant new commercial market in consumer wellness.

"The move would also create a significant new business opportunity for consumer health investors and startup founders in the wellness industry."

Demand is already surging in gray markets: "Imports from China of hormone and peptide compounds, including GLPs, melanotan II and others, reached $328 million in the first nine months of 2025, about twice the $164 million in the same period of 2024."

Telehealth platforms are the most obvious beneficiaries, given their playbook with GLP-1 compounding: "For telehealth companies like Ro, Solace and Hims & Hers Health, whose ability to produce compound versions of these weight-loss drugs created new business lines, peptides would be an obvious next move."

---

Theme 2: PE Liquidity Crisis Fuels the Rise of NAV Lending

With PE holding periods at decade-long highs, GPs are turning to NAV loans — borrowing against portfolio assets — to manufacture liquidity without forcing exits.

"In 2025, the median holding period of an existing US PE-backed company reached 4.4 years, the longest period in more than a decade."

The scale of the opportunity is enormous and still early: "The NAV loan market is estimated to be $100 billion in size and is projected to grow to over $600 billion by 2030."

17Capital's fundraising trajectory illustrates the momentum — its NAV fund ($7.5B) has already surpassed its sixth preferred equity fund ($5.5B) in size, despite NAV lending funds having launched only in 2020.

---

Theme 3: Private Credit Secondary Market Emerging — With Growing Pains

A nascent secondary market for private credit loans is forming as redemptions force managers to seek liquidity, but supply is currently outpacing demand.

"More private credit loans are up for sale than ever before on a nascent secondary market, as investor redemptions push credit managers to boost liquidity. But so far, the supply of loans is outpacing demand."

Meanwhile, risk appetite in leveraged finance is broadly contracting: "Only 11% of respondents expect leverage multiples on buyouts to increase, while 53% expect them to decrease... indicating a pullback in risk appetite."

---

Theme 4: European PE Pivoting to Industrial/Tangible Assets Amid AI Uncertainty

European PE is rotating away from tech and toward physical, industrial assets, with 56 deals already closed in 2026 totaling €9.1 billion ($10.5B).

"About 56 deals have closed in the industrials sector in Europe so far this year, totaling €9.1 billion (about $10.5 billion), and the continent has several major deals in the pipeline."

The shift is explicitly framed as a hedge against AI-driven uncertainty, per the linked source: "European PE refocuses on tangible assets amid AI uncertainty."

---

2. Contrarian Perspectives

Peptides Are NOT the Next GLP-1 — The Risk Profile Is Materially Different

The consensus framing treats peptides as the next GLP-1 wave for telehealth, but the article flags a critical distinction: the clinical evidence base is far thinner.

"GLP-1s have been extensively tested in Phase 3 large-scale human trials and target a well-studied receptor axis for insulin, while these 14 banned peptides have not received the same scrutiny."

The market is being driven by cultural momentum, not clinical proof: "The peptides market has taken off in the US, buoyed by small studies claiming anti-aging, anti-inflammatory and muscle-building properties." If adverse effects emerge post-commercialization, the entire cottage industry could face severe backlash — a risk that bullish investor narratives are currently discounting.

---

Legalization Reduces, Not Increases, the Long-Term Gray Market Advantage

The intuitive read is that legalization creates new entrants and erodes the head start of existing gray market operators. But the article suggests the opposite framing: regulation helps incumbents by eliminating the unsafe, uncontrolled competition they currently face.

"Allowing peptides to be manufactured and sold through regulated channels helps prevent consumers from using the gray markets that are currently selling them." — Ben Riccio, PitchBook emerging technology analyst

Regulated channels raise the barrier to entry, favoring established telehealth platforms with prescription infrastructure already in place.

---

Korea, Not China, May Win the Robotics Race on What Matters Most

The dominant narrative in tech circles is that China's manufacturing scale gives it an insurmountable robotics advantage. The article pushes back, noting South Korea is winning on the harder engineering problem.

"Though China wins the robotics race in terms of scale and manufacturing capabilities, South Korean robots are excelling in the engineering problem of dexterous manipulation." — The Korea Herald

Dexterous manipulation — the ability to handle complex, unstructured tasks — is the key bottleneck for real-world robotics deployment, making Korea's edge potentially more strategically durable than China's volume advantage.

---

3. Companies Identified

---

4. People Identified

---

5. Operating Insights

For Telehealth Operators: Move Now on Prescription Infrastructure for Peptides

The window before full FDA legalization is the time to build the prescription fulfillment and compounding pharmacy relationships needed to service the peptide market at scale. GLP-1 incumbents already have the rails; the advantage will accrue to those who activate them fastest.

"If the FDA goes through with the reversal, consumers will still need a prescription to access the drugs, but they'll be far easier to come by than they are today."

The gray market demand signal is already validated — imports doubled year-over-year — so operators should treat this as a demand-confirmed, supply-constrained opportunity, not a speculative one.

---

For PE Fund Managers: Preferred Equity Is a GP Balance Sheet Tool, Not a Portfolio Tool

Operators and fund managers considering fund finance solutions should understand that preferred equity and NAV loans serve fundamentally different purposes — and the preferred equity market is structurally capped relative to NAV lending.

"Preferred equity has morphed into a tool used mainly by private equity managers to run their own businesses... They use it to finance their GP commitments, management fees and carried interest payments. Call it a $400 billion market versus a $4 trillion one."

NAV loans, by contrast, are a portfolio-level liquidity tool with far greater addressable market — relevant for GPs managing aging portfolios who need to generate LP distributions without exiting assets.

---

6. Overlooked Insights

Data Centers Are Creating Measurable Physical Heat Externalities

Briefly mentioned but potentially significant for real estate, infrastructure, and ESG investors: the energy demands of data centers are generating "heat islands" extending as far as six miles from facilities. This is an emerging environmental liability and a regulatory risk vector that is not yet priced into most data center investment underwriting.

"Energy required by data centers is creating 'heat islands' as far as six miles out from the facilities."

---

PE Consolidation of Fire Safety Equipment Is a Public Safety and Regulatory Risk

PE firms now control 70–80% of fire emergency vehicle production in the US, and prices are rising faster than inflation — creating both a public safety concern and a potential regulatory intervention risk that could affect portfolio valuations in the sector.

"PE firms now control 70% to 80% of fire emergency vehicle production, and with prices on safety equipment outpacing inflation, emergency preparedness concerns are rising."